TORNTPHARM

Torrent Pharmaceuticals share price & results

Torrent Pharmaceuticals Limited· Healthcare

Torrent Group's pharma major - branded generics in India, Brazil & Germany; generics in the US

₹4,668.8 −0.48%
MCap ₹1.8L Cr Price to earnings (TTM to Sept 2026) 82.33× Return on equity (TTM to Sept 2026) 11.82%

Free account: unlock 50 concall reads/mo, 5 full guidance ledgers, and same-day TORNTPHARM alerts.

Results to: Sept 2026 Latest analysed call: Q2 FY27 Ownership as of: Sept 2026
TORNTPHARM at a glance Plain-English snapshot from filed results & analysed earnings calls

Guidance Track Record

Management guidance vs. actual results

1 of 6 judged targets kept · 12 open · verdicts reflect calls analysed to Q1 FY27.

Torrent Pharmaceuticals Limited management guidance track record on Inve: 18 targets tracked across analysed earnings calls (1 achieved, 5 missed, 12 open).

Delivering on Growth (1/1 achieved), while Operations (1 needs watch) is lagging.

TargetOriginal wordingSaidLatest callVerdict
Growth India Field Force (MRs)
Add 100-200 by end of FY25; later revised to 7,000 by end of FY26
Q2 FY25
Q1 FY27:Promise achieved in FY26. This metric is now superseded by the combined entity's field force tracking post-JB merger.
Achieved
Operations Net Debt
Net Cash by FY26
Q2 FY25
Q1 FY27:Original target remains missed. However, Net Debt/EBITDA improved to 2.07x from 2.3x in the previous quarter, showing progress towards the revised deleveraging goal.
Missed
Operations Cost Synergies
₹400-450 crores over 2-3 years
Q3 FY26
Q1 FY27:Synergies are being realized 'sooner than expected'. The year 1 target of ~₹90 cr is now guided to be 'definitely... above 100' cr. The pace of realization has been revised up.
Revised Up

Source: Inve Guidance Tracker for Torrent Pharmaceuticals Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

5 of Torrent Pharmaceuticals Limited's 18 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 15 more targets are in the full ledger.

Get the Inve app for Android on Google Play Get the Inve app for Android on Google Play Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Latest analysed call · Q2 FY27 · 23 Oct 2026

Q2 FY27: Torrent Pharmaceuticals Limited Q2 FY27

Torrent Pharma delivered strong Q2 FY27 results with consolidated revenue advancing 51% YoY to ₹4,979 crores and EBITDA rising 54% YoY to ₹1,666 crores, aided by the merger of JB effective July 8, 2026. The base India branded business outperformed industry growth at 20% YoY, supported by new launches and Curatio's 34% growth. While transient integration disruptions impacted JB's international business and Germany faced structural pricing headwinds, management expects overall JB growth to rebound to double digits in H2 FY27 and cost synergies to materialize ahead of the original three-year sche

What management highlighted

  • Consolidated revenues grew 51% YoY to ₹4,979 crores and operating EBITDA grew 54% YoY to ₹1,666 crores
  • Torrent base India business recorded 20% YoY growth to ₹2,181 crores versus IPM growth of 12%
  • Curatio business maintained strong momentum, growing 34% in Q2 and H1, and now contributes 7-8% of base India sales

Source: Inve analysis of Torrent Pharmaceuticals Limited’s Q2 FY27 earnings call · to 23 Oct 2026

Compare across 8 analysed calls

Price & Snapshot

₹4,668.8 −0.48% · −₹22.4

Last close 17 Nov 2026 · NSE · INR · Source: Inve

Performance +21.8% 1Y

₹4.0k₹4.5k₹5.0kNov 25Dec 25Feb 26Mar 26May 26Jun 26Aug 26Sept 26Nov 26Q2 FY26 — 14 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 22 May 2026Q1 FY27 — 30 Jul 2026Q2 FY27 — 23 Oct 2026

1Y: ₹3,831.8 on 14 Nov 2025 → ₹4,668.8. High ₹5,122.8 (31 Jul 2026), low ₹3,686.5 (21 Nov 2025).

Previous close
₹4,691.2
Market cap
₹1.8L Cr
52-week range
₹3,686.5 – ₹5,122.8
One year
+22.24%
Price to earnings (TTM to Sept 2026)
82.33×
Return on equity (TTM to Sept 2026)
11.82%

Reported

Key financial metrics & valuation ratios

Revenue: 4,145 ₹ crore (+50.1% YoY) · Net profit: 498 ₹ crore (−16.6% YoY) · Return on equity: 11.82 % (+0.9 pts). Every row keeps its filed period and basis.

MetricValueChangeBasisPeriodNote
Revenue4,145 ₹ crore+50.1% YoYQuarterly, as filedQuarter to Sept 2026Revenue from operations as filed.
Operating margin38.0 %−1.0 pts YoYOperating profit / revenueQuarter to Sept 2026For the quarter; a change is in percentage points.
Net profit498 ₹ crore−16.6% YoYQuarterly, as filedQuarter to Sept 2026Profit after tax as filed.
Return on equity11.82 %+0.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin17.07 %−0.2 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026
(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)42.06 %+14.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Sept 2026
Revenue change against the same period one year earlier.

Source: Quarterly results & TTM/FY financial ratios · to Sept 2026

Customers, suppliers & partners

Customers, suppliers & partner mentions

Named customers, suppliers, and partners mentioned on recent earnings calls. Click any row to read the disclosure.

Counterparties named by Torrent Pharmaceuticals Limited

  • Torrent Pharmaceuticals Limited → acquires or invests in → JB Chemicals & Pharmaceuticals Limited (JBCHEPHARM)

    Acquires / invests · Closed / completed · Q1 FY27
  • Torrent Pharmaceuticals Limited → acquires or invests in → Novartis Ophthalmology Franchise (JB Deal)

    Acquires / invests · Closed / completed · INR 960 crores · Q2 FY27
  • Torrent Pharmaceuticals Limited → acquires or invests in → JB Chemicals & Pharmaceuticals (JB)

    Acquires / invests · Closed / completed · Q2 FY27
  • Torrent Pharmaceuticals Limited → acquires or invests in → JB Pharma

    Acquires / invests · Announced · Q4 FY26

Similar pressures reported by peers

Tailwind coverage is not available yet.
  • Government-mandated price decreases and high-value tender losses continue to hurt the…

    53 other companies · Regulatory policy · Q2 FY27
  • Customer concentration (3-4 buyers holding 90% share) and expected competitor entry on…

    9 other companies · Pricing discipline · Q2 FY27

Mentions over time

Q1 2026 – Q3 2026

From available earnings-call summaries. Disclosures are management statements, not independently verified transactions.

Company Reference

Symbol
NSE:TORNTPHARM
Exchange
NSE
Currency
INR

What Torrent Pharmaceuticals Limited does

Sourced to annual report & earnings calls.

Torrent Pharmaceuticals is the flagship pharma company of the Torrent Group, developing, manufacturing and marketing formulations through two core segments: branded generics (India, Brazil and emerging markets) and generics (United States, Germany, UK and other regulated markets). It focuses on chronic and high-burden therapies - cardiovascular, CNS, gastro-intestinal, anti-diabetic, dermatology, pain management and gynaecology - and sells in more than 50 countries. In January 2026 it acquired a controlling stake in J.B. Chemicals & Pharmaceuticals (JB Pharma), lifting the combined entity to 5th rank in the Indian pharmaceutical market.

Segments

  • Branded Generics (BGx)
  • Generics (Gx)
Manufacturing facilities
8 world-class facilities plus a dedicated R&D centre
Countries sold in
50+
Employees
18,500+ across 12 countries
Rank in Indian pharma market (combined with JB Pharma)
5th largest
India field force (combined with JB Pharma)
9,000+
Therapy leadership in India
No.1 in Cardiac; Top 5 in CNS, GI, Pain Management and Dermatology
Founded 1959Headquarters Ahmedabad, Gujarat, IndiaEmployees 18,500 (FY2025-26) Company website

How the price took the results

Moved an average of ±0.6% across the last 4 priced result releases

Close before → close after
QuarterReleaseRevenue (₹ Cr) Net profit (₹ Cr)Rev YoYBefore → AfterReaction
Q2 FY2723 Oct 264,145 498+50.1%₹4,615.3 → ₹4,524.4−2.0%
Q1 FY2730 Jul 264,158 492+58.9%₹4,878.5 → ₹4,872.1−0.1%
Q4 FY2622 May 263,445 309+41.6%₹4,469.2 → ₹4,486.2+0.4%
Q3 FY2613 Feb 262,599 577+9.3%₹4,077.2 → ₹4,078+0.0%

The move from the last close before each results date to the first close on or after it — the market's first read on the quarter alongside what was filed.

Your own record

Start an Inve Case & results alerts for Torrent Pharmaceuticals Limited

Free account: one Inve Case, 50 concall reads/mo, 5 full ledgers, and results-day alerts.

Write why you follow Torrent Pharmaceuticals Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance, and notifies you when a new call moves your thesis.

Keep reading

Other Healthcare companies

PEER COMPARISON
Median ₹1.3L Cr Mkt Cap
₹0 Cr₹2.0L Cr₹4.0L Cr₹6.0L CrTorrent Pharmaceuticals Limited (TORNTPHARM): ₹1.8L Cr₹1.8L CrTORNTPHARMSun Pharmaceutical Industries Limited (SUNPHARMA): ₹4.6L Cr₹4.6L CrSUNPHARMADivi's Laboratories Limited (DIVISLAB): ₹3.0L Cr₹3.0L CrDIVISLABLaurus Labs (LAURUSLABS): ₹1.3L Cr₹1.3L CrLAURUSLABSApollo Hospitals Enterprise Limited (APOLLOHOSP): ₹1.3L Cr₹1.3L CrAPOLLOHOSPZydus Lifesciences Limited (ZYDUSLIFE): ₹1.2L Cr₹1.2L CrZYDUSLIFEDr. Reddy's Laboratories Limited (DRREDDY): ₹1.1L Cr₹1.1L CrDRREDDYCipla Limited (CIPLA): ₹1.1L Cr₹1.1L CrCIPLAAurobindo Pharma Limited (AUROPHARMA): ₹1.1L Cr₹1.1L CrAUROPHARMA

All Healthcare companies → · Healthcare earnings growth →

Quick Answers

Frequently asked questions on Torrent Pharmaceuticals Limited

Compiled directly from TORNTPHARM's filed financial statements, earnings call transcripts, and ownership disclosures.

How did Torrent Pharmaceuticals Limited (TORNTPHARM) perform in its latest reported quarter (Sept 2026)?

For the quarter ended Sept 2026, Torrent Pharmaceuticals Limited reported revenue of ₹4.1k Cr, net profit of ₹498 Cr, an operating margin of 38.0%. Diluted earnings per share stood at ₹13.09.

How is Torrent Pharmaceuticals Limited (TORNTPHARM) valued today, and what growth does the stock price imply?

Torrent Pharmaceuticals Limited (TORNTPHARM) trades at ₹4,668.8, with a market capitalization of ₹178.7k Cr, a trailing P/E multiple of 82.33×, return on equity (ROE) of 27.43%, ROCE of 15.19%.

Did Torrent Pharmaceuticals Limited (TORNTPHARM) management keep or miss its earnings call guidance?

Across 18 management guidance targets tracked from Torrent Pharmaceuticals Limited's earnings calls, 1 was achieved, 5 missed, and 12 remain open (17% delivered among resolved targets). Sampled guidance includes India Field Force (MRs): "Add 100-200 by end of FY25; later revised to 7,000 by end of FY26" (stated in Q2 FY25, current status: achieved).

Who owns Torrent Pharmaceuticals Limited (TORNTPHARM) — promoters, FIIs, DIIs, and mutual funds?

As of Sept 2026, Promoters hold 60.8%, FIIs hold 17.2%, DIIs hold 13.4%, Public shareholders hold 8.5%.

What did Torrent Pharmaceuticals Limited (TORNTPHARM) management cover on its latest concall (Q2 FY27)?

On its Q2 FY27 (Oct 2026) concall, Torrent Pharma delivered strong Q2 FY27 results with consolidated revenue advancing 51% YoY to ₹4,979 crores and EBITDA rising 54% YoY to ₹1,666 crores, aided by the merger of JB effective July 8, 2026. The base India branded business outperformed industry growth at 20% YoY, supported by new launches and Curatio's 34% growth. While transient integration disruptions impacted JB's international business and Germany faced structural pricing headwinds, management expects overall JB growth to rebound to double digits in H2 FY27 and cost synergies to materialize ahead of the original three-year sche. Read Torrent Pharmaceuticals Limited Q2 FY27 concall summary →